Artelo Biosciences Files Provisional Patent for ART27.13 in Obesity Treatment, Including GLP-1 Combination

Artelo Biosciences, Inc. (ARTL) announced on Wednesday the filing of a provisional patent application covering ART27.13 for the treatment of obesity, both as a standalone therapy and in combination with GLP-1 receptor agonists such as semaglutide. The filing follows recent nonclinical study findings supporting the drug candidate's use in obesity treatment. No financial terms or timeline details were disclosed. The expanded patent coverage is intended to strengthen the company's intellectual property position around ART27.13. Artelo did not provide additional data on the study results or regulatory next steps.